Drawing for AETERNA ZENTARIS

USPTO serial 78437128

AETERNA ZENTARIS

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
RINGLE, JAMES W
Law office
TMO LAW OFFICE 111 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with AETERNA ZENTARIS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Mark I. Peroff

Mark I. Peroff Wilson Keadjian Browndorf LLP114 W. Forty Seventh Street - 18th FloorNEW YORK, NY 10036UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations used for the treatment of cancer, pharmaceutical preparations administered as a radiosensitizer and used for the treatment of cancer, pharmaceutical preparations used for the treatment of urological diseases, pharmaceutical preparations used for the treatment of hormonal disorders, peptides-containing pharmaceutical preparations used for hormonal and tumors treatments, pharmaceutical preparations used for the treatment of endocrine diseases, pharmaceutical preparations used for the treatment of carcinoid tumors, pharmaceutical preparations used for the treatment of hematological diseases, pharmaceutical preparations used for the treatment of age-related diseases, pharmaceutical preparations used for the treatment of ophtalmological disorders, pharmaceutical preparations used for the treatment of reproductive system disorders, pharmaceutical preparations used for the treatment of endometriosis, pharmaceutical preparations used for the treatment of uterine myoma, pharmaceutical preparations used for the treatment of non-malignant tumors, pharmaceutical preparations used for the treatment of benign prostatic hyperplasia (BPH), pharmaceutical preparations used for the treatment of tropical diseases, pharmaceutical preparations used for the treatment of infectious disease, pharmaceutical preparations used for the treatment of leishmaniasis, pharmaceutical preparations used for the treatment of obesity, pharmaceutical preparations used for the treatment of diabetes and disorders related to diabetes, pharmaceutical preparations containing conjugated and non-conjugated cytotoxic products used to selectively and specifically target certain types of cancer; pharmaceutical preparations used as a tubulin inhibitor, pharmaceutical preparations based on LHRH antagonists platform used for the treatment of certain types of cancer and endocrine disorders, pharmaceutical preparations based on bombesin antagonist platform used for the treatment of certain types of cancer, pharmaceutical preparations based on inhibitors of the Akt pathway used for the treatment of certain types of cancer, pharmaceutical preparations based on angiogenesis inhibitors platform with multiple mechanisms of action used for the treatment of certain types of cancer, pharmaceutical preparations used to induce apoptosis, pharmaceutical preparations used to stimulate growth hormone secretagogue (GHS)ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Nov 27, 2017MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Nov 27, 2017ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jun 1, 2017TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 1, 2017CNSIINQUIRY AS TO SUSPENSION MAILED—
May 1, 2017CNSISUSPENSION INQUIRY WRITTEN—
Nov 1, 2016CNSLLETTER OF SUSPENSION MAILED—
Nov 1, 2016CNSLSUSPENSION LETTER WRITTEN—
Oct 31, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 31, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 24, 2016ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Sep 1, 2016ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 1, 2016REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 17, 2016GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
May 17, 2016GNSIINQUIRY TO SUSPENSION E-MAILED—
May 17, 2016CNSISUSPENSION INQUIRY WRITTEN—
Nov 17, 2015GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Nov 17, 2015GNSLLETTER OF SUSPENSION E-MAILED—
Nov 17, 2015CNSLSUSPENSION LETTER WRITTEN—
Oct 27, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 27, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 17, 2015ALIEASSIGNED TO LIE—
Sep 28, 2015ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Apr 1, 2015GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Apr 1, 2015GNSIINQUIRY TO SUSPENSION E-MAILED—
Apr 1, 2015CNSISUSPENSION INQUIRY WRITTEN—
Oct 1, 2014GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Oct 1, 2014GNSLLETTER OF SUSPENSION E-MAILED—
Oct 1, 2014CNSLSUSPENSION LETTER WRITTEN—
Sep 24, 2014TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 24, 2014CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 17, 2014ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Mar 26, 2014GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Mar 26, 2014GNSIINQUIRY TO SUSPENSION E-MAILED—
Mar 26, 2014CNSISUSPENSION INQUIRY WRITTEN—
Sep 26, 2013GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Sep 26, 2013GNSLLETTER OF SUSPENSION E-MAILED—
Sep 26, 2013CNSLSUSPENSION LETTER WRITTEN—
Sep 25, 2013TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Sep 25, 2013TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 25, 2013CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 25, 2013ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Apr 10, 2013GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Apr 10, 2013GNSIINQUIRY TO SUSPENSION E-MAILED—
Apr 10, 2013CNSISUSPENSION INQUIRY WRITTEN—
Oct 10, 2012GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Oct 10, 2012GNSLLETTER OF SUSPENSION E-MAILED—
Oct 10, 2012CNSLSUSPENSION LETTER WRITTEN—
Oct 9, 2012TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 8, 2012CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 8, 2012ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Apr 6, 2012GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Apr 6, 2012GNSIINQUIRY TO SUSPENSION E-MAILED—
Apr 6, 2012CNSISUSPENSION INQUIRY WRITTEN—
Nov 10, 2011ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 10, 2011REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Oct 6, 2011GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Oct 6, 2011GNSLLETTER OF SUSPENSION E-MAILED—
Oct 6, 2011CNSLSUSPENSION LETTER WRITTEN—
Oct 5, 2011TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 5, 2011CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 5, 2011ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Apr 6, 2011GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Apr 6, 2011GNSIINQUIRY TO SUSPENSION E-MAILED—
Apr 6, 2011CNSISUSPENSION INQUIRY WRITTEN—
Oct 25, 2010TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Oct 6, 2010CNSLLETTER OF SUSPENSION MAILED—
Oct 5, 2010CNSLSUSPENSION LETTER WRITTEN—
Sep 30, 2010TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 30, 2010CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 30, 2010ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Apr 20, 2010CNSIINQUIRY AS TO SUSPENSION MAILED—
Apr 20, 2010CNSISUSPENSION INQUIRY WRITTEN—
Apr 20, 2010RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Oct 20, 2009CNSLLETTER OF SUSPENSION MAILED—
Oct 19, 2009CNSLSUSPENSION LETTER WRITTEN—
Oct 14, 2009TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 14, 2009CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 14, 2009ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Apr 15, 2009CNSIINQUIRY AS TO SUSPENSION MAILED—
Apr 14, 2009CNSISUSPENSION INQUIRY WRITTEN—
Apr 14, 2009RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Oct 14, 2008CNSLLETTER OF SUSPENSION MAILED—
Oct 12, 2008CNSLSUSPENSION LETTER WRITTEN—
Oct 11, 2008TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 11, 2008CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 7, 2008ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Oct 6, 2008CNSIINQUIRY AS TO SUSPENSION MAILED—
Oct 6, 2008CNSISUSPENSION INQUIRY WRITTEN—
Oct 1, 2008RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Apr 1, 2008RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Mar 28, 2008RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Mar 28, 2008ALIEASSIGNED TO LIE—
Sep 20, 2007RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Mar 20, 2007RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Sep 19, 2006CNSLLETTER OF SUSPENSION MAILED—
Sep 18, 2006CNSLSUSPENSION LETTER WRITTEN—
Aug 7, 2006TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 18, 2006CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 18, 2006TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 14, 2006CNSIINQUIRY AS TO SUSPENSION MAILED—
Feb 14, 2006CNSISUSPENSION INQUIRY WRITTEN—
Aug 9, 2005CNSLLETTER OF SUSPENSION MAILED—
Aug 8, 2005CNSLSUSPENSION LETTER WRITTEN—
Aug 5, 2005TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 1, 2005CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 1, 2005TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 7, 2005CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 5, 2005CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 21, 2005DOCKASSIGNED TO EXAMINER—
Jun 23, 2004NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance